Placeholder

Globalization

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

SKU: 1474. Category: .

Product Description

IMS’s 2009 Pharmaceutical Market Forecast reports that growth rates will level out and hold steady with 2008 levels. The global market is expected to total more than $820 billion in 2008, a growth rate of 4.5% to 5.5%. Further, IMS analysts predict that market forces that have been gaining momentum for the past few years — among them, the shift in growth from developed countries to emerging ones, specialist-driven and niche products playing a larger role, blockbuster drugs losing patent protection, and the rising influence of regulators and payers on healthcare decisions — will play out in full during 2009. Layered on top is the uncertainty in the global economic environment and its effect on demand. These same analysts note, however, that the global pharmaceutical…

Sidebar:
Key Dynamics Shaping the Global Market

Experts
William D. Abajian. Senior Executive Advisor, Global Strategic Alliances and Business Development, Generex Biotechnology Corp., Toronto, Canada; Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies. For more information, visit generex.com.
Prabir K. Basu, Ph.D. Executive Director, National Institute for Pharmaceutical Technology and Education (NIPTE), Des Plaines, Ill.; NIPTE is a nonprofit organization dedicated to basic research in pharmaceutical development and manufacturing science, and is supported by 11 universities in the United States. For more information, visit nipte.org. Dr. Basu is also the Managing Director of Pharmaceutical Technology and Education Center (PTEC), an interdisciplinary research institute at Purdue University.
William C. Bertrand, J.D. Executive VP, Legal Affairs, General Counsel and Corporate Compliance Officer, MedImmune, Gaithersburg, Md.; MedImmune is a biotechnology company focused on infection, oncology, respiratory disease, inflammation, cardiovascular, gastrointestinal disease, and neuroscience. For more information,visit medimmune.com.
Dale B. Evans, Ph.D. President and CEO of Omnicare Clinical Research, King of Prussia, Pa.; Omnicare Clinical Research is a Phase I to IV contract research organization serving the biopharmaceutical and medical-device industries. For more information, visit omnicarecr.com.
Leyla Feyzioglu. President, Rekmar Brand Innovation, Istanbul, Turkey; Rekmar is a marketing and advertising agency. For more information, contact rekmar@rekmar.com.tr.
Mark A. Goldberg, M.D. Chief Operating Officer, Parexel International, Waltham, Mass.; Parexel partners with drug developers and medical-device manufacturers looking to bring innovative new products to market. For more information, visit parexel.com.
Terry Hisey. Vice Chairman and U.S. Life Sciences Leader, Deloitte LLP, New York; Deloitte provides audit, consulting, financial advisory, risk management, and tax services to selected clients. For more information, visit deloitte.com.
Ross Horsburgh, MBChB. VP, Global Clinical Development — Asia/Pacific, Kendle, Cincinnati; Kendle is a global clinical research organization providing the full range of early- to late-stage clinical development services for the global biopharmaceutical industry. For more information, visit kendle.com.
Nicholas Landekic. President, CEO, and Founder, PolyMedix Inc., Radnor, Pa.; PolyMedix develops novel, therapeutic drug products for serious, life-threatening acute disorders. For more information, visit polymedix.com.
Clive A. Meanwell, M.D., Ph.D. Chairman and CEO, The Medicines Company, Parsippany, N.J.; The Medicines Company is focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. For more information, visit themedicinescompany.com.
Richard T. Minoff. President and CEO, Dorland Global Corp., Philadelphia; Dorland is a full-service, integrated marketing communications firm. For more information, visit dorland.com.
Mark Perlotto. Executive VP, Managing Director, Adair Greene-McCann, Atlanta; Adair Greene is a full-service healthcare communications agency. For more information, visit aghealthcare.com.
Nagaraja Srivatsan. VP and Head of North America, Life Sciences, Cognizant, Teaneck, N.J.; Cognizant is a provider of information technology, consulting, and business process outsourcing services. For more information, visit cognizant.com.
Roger L. Williams, M.D. Executive VP and CEO, U.S. Pharmacopeial Convention, Rockville, Md.; USP is an official public standards-setting authority for all prescription and OTC medicines and other healthcare products manufactured or sold in the United States. For more information, visit usp.org.

FEEDBACK